AAMU
PACB icon

Amundi Asset Management US’s Pacific Biosciences PACB Stock Holding History

Amundi Asset Management US’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$8.61M Sell
258,500
-434,339
-63% -$15.2M 0.01% 883
2020
Q4 		$18M Buy
+692,839
New +$11.8M 0.02% 664

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amundi Asset Management US's PACB Position: Q1 2021 in Review

Amundi Asset Management US reduced its Pacific Biosciences (PACB) stake by 63% in Q1 2021, selling an estimated $15.2M and leaving 258,500 shares worth $8.61M. The position accounts for 0.01% of the portfolio, ranked #883.

Amundi Asset Management US first reported a position in PACB in Q4 2020 and has held it in 2 quarters since. The position peaked at $18M in Q4 2020. 263 funds tracked by Wall St. Rank hold PACB as of Q1 2021.

  • Amundi Asset Management US held 258,500 shares of Pacific Biosciences worth $8.61M as of Q1 2021.
  • Amundi Asset Management US sold 434,339 Pacific Biosciences shares in Q1 2021, an estimated $15.2M.
  • Pacific Biosciences made up 0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #883 holding.
  • Amundi Asset Management US first reported a position in Pacific Biosciences in Q4 2020 and has held it in 2 quarters since.
  • Amundi Asset Management US's Pacific Biosciences position peaked at $18M in Q4 2020.
  • 263 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.